Nutrinia

The company targets patient populations with high levels of unmet medical need, primarily preterm newborns with intestinal malabsorption and infants suffering from Short Bowel Syndrome (SBS). For these conditions, there are currently no approved therapeutic treatments. Nutrinia's lead product is a reconstituted powder formulation of insulin that can be administered orally or via a feeding tube, mixed with breast milk, formula, or saline. This product aims to accelerate intestinal maturation, reduce dependence on parenteral nutrition, and consequently lower the risk of life-threatening complications like sepsis and infection associated with feeding tubes. By enhancing the gut's ability to absorb nutrients, the therapy can shorten the time infants require intravenous feeding and hospitalization in the neonatal intensive care unit (NICU).

Nutrinia's business model is centered on pharmaceutical development and registration, pursuing orphan drug designation to address these rare conditions. In June 2015, the U.S. FDA granted orphan drug designation for its product, NTRA-9620, for the treatment of SBS. The company has secured significant funding to advance its clinical programs, raising a total of $43.1 million over several rounds. A notable Series D funding round in August 2016, led by TPG Biotech, raised $30 million to finance two pivotal trials in the US and Europe aimed at securing registration for its key indications. This followed a Series C round of $12 million in 2014 and earlier funding stages. The company's progress is supported by a strong biological rationale and compelling preclinical and clinical trial data.